deCODE genetics Announces Webcast of Presentation at the Nasdaq U.S. Small Cap Conference

Feb 06, 2006, 00:00 ET from deCODE genetics

    REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -. deCODE genetics
 (Nasdaq:   DCGN) today announced that its presentation at Nasdaq's U.S. Small
 Cap Conference will be webcast live. deCODE CEO Dr. Kari Stefansson will
 provide an overview of the company's drug development programs and business.
     The presentation will be delivered at 10am GMT/5am EST on Wednesday,
 February 8, 2006, at the Merrill Lynch Financial Centre in London. The webcast
 can be accessed through the Investors page on deCODE's website,
 http://www.decode.com, or through the Nasdaq website at
 http://investors.nasdaq.com. The webcast will be archived for at least one
 week on both sites. Those interested in listening should log on a few minutes
 in advance, in order to download any software or complete any sign-in that may
 be required.
 
     About deCODE
     deCODE genetics (Nasdaq:   DCGN) is a biopharmaceutical company applying its
 discoveries in human genetics to the development of drugs for common diseases.
 deCODE is a global leader in gene discovery -- our population approach and
 resources have enabled us to isolate key genes contributing to major public
 health challenges from cardiovascular disease to cancer, genes that are
 providing us with drug targets rooted in the basic biology of disease. deCODE
 is also leveraging its expertise in human genetics and integrated drug
 discovery and development capabilities to offer innovative products and
 services in DNA-based diagnostics, bioinformatics, genotyping, structural
 biology, drug discovery and clinical development. deCODE is delivering on the
 promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
 
     Contact:
     deCODE genetics
     Stefan Arnason
     +354 570 1995
     ir@decode.is
 
 

SOURCE deCODE genetics
    REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -. deCODE genetics
 (Nasdaq:   DCGN) today announced that its presentation at Nasdaq's U.S. Small
 Cap Conference will be webcast live. deCODE CEO Dr. Kari Stefansson will
 provide an overview of the company's drug development programs and business.
     The presentation will be delivered at 10am GMT/5am EST on Wednesday,
 February 8, 2006, at the Merrill Lynch Financial Centre in London. The webcast
 can be accessed through the Investors page on deCODE's website,
 http://www.decode.com, or through the Nasdaq website at
 http://investors.nasdaq.com. The webcast will be archived for at least one
 week on both sites. Those interested in listening should log on a few minutes
 in advance, in order to download any software or complete any sign-in that may
 be required.
 
     About deCODE
     deCODE genetics (Nasdaq:   DCGN) is a biopharmaceutical company applying its
 discoveries in human genetics to the development of drugs for common diseases.
 deCODE is a global leader in gene discovery -- our population approach and
 resources have enabled us to isolate key genes contributing to major public
 health challenges from cardiovascular disease to cancer, genes that are
 providing us with drug targets rooted in the basic biology of disease. deCODE
 is also leveraging its expertise in human genetics and integrated drug
 discovery and development capabilities to offer innovative products and
 services in DNA-based diagnostics, bioinformatics, genotyping, structural
 biology, drug discovery and clinical development. deCODE is delivering on the
 promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
 
     Contact:
     deCODE genetics
     Stefan Arnason
     +354 570 1995
     ir@decode.is
 
 SOURCE  deCODE genetics